Evidence map›Paper›PMID 41102154›Full record

ArticleJournal of medicinal chemistry2025

Development of Lipopeptides as Orthoflavivirin Inhibitors with Low Micromolar Broad-Spectrum Antiorthoflaviviral Activity.

Lorenzo Cavina, Anna Alocén Portillo, Mike P A Balmer, Jenny C Dammer, Danae Schillemans, Said Hakim Hamdani, Bart Ackerschott, Cindy E J Dieteren, Byron E E Martina, Bernd N M van Buuren and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lorenzo CavinaInstitute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands.
Anna Alocén PortilloInstitute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands.
Mike P A BalmerInstitute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands.
Jenny C DammerInstitute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands.
Danae SchillemansInstitute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands.
Said Hakim HamdaniProtinhi Therapeutics, Transistorweg 5, 6534 AT Nijmegen, The Netherlands.
Bart AckerschottProtinhi Therapeutics, Transistorweg 5, 6534 AT Nijmegen, The Netherlands.
Cindy E J DieterenProtinhi Therapeutics, Transistorweg 5, 6534 AT Nijmegen, The Netherlands.
Byron E E MartinaProtinhi Therapeutics, Transistorweg 5, 6534 AT Nijmegen, The Netherlands.
Bernd N M van BuurenProtinhi Therapeutics, Transistorweg 5, 6534 AT Nijmegen, The Netherlands.
Alexandra RockstrohDepartment of Infection Research and Diagnostics, Fraunhofer Institute for Cell Therapy and Immunology, Perlickstr. 1, 04103 Leipzig, Germany.
Sebastian UlbertDepartment of Infection Research and Diagnostics, Fraunhofer Institute for Cell Therapy and Immunology, Perlickstr. 1, 04103 Leipzig, Germany.
Pedro H H HermkensHermkensPharmaConsultancy B.V., Gripper 1, 5348 KZ Oss, The Netherlands.
Montse Llinàs BrunetProtinhi Therapeutics, Transistorweg 5, 6534 AT Nijmegen, The Netherlands.
Daniel GironésInstitute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands.
Martin C FeitersInstitute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands.ORCID 0000-0003-0130-835X
Floris P J T RutjesInstitute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands.ORCID 0000-0003-1538-3852

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Orthoflaviviral infections increasingly impact the global population; no specific therapeutic treatments are available. The orthoflaviviral protease NS2B-NS3 is a promising target for antiviral drug development. Here, we present the design, synthesis, structure-activity relationship (SAR), and in vivo PK study of a novel lipopeptide scaffold emerging from exploration of the previously investigated polycationic geminoids

Indexed as

Antiviral AgentsLipopeptidesProtease InhibitorsViral Nonstructural ProteinsAnimalsDengue VirusHumansMiceMice, Inbred BALB CMicrobial Sensitivity TestsStructure-Activity RelationshipWest Nile virusZika VirusAntiviral AgentsLipopeptidesProtease InhibitorsViral Nonstructural Proteins

Identifiers

PMID41102154
PMCPMC12621197

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.